| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 50g |
|
||
| Other Sizes |
|
Purity: ≥98%
Capecitabine (formerly RO 09-1978; RO-09-1978; RO09-1978; CAPE; Trade name: Xeloda) is an anticancer chemotherapeutic medication approved for treating breast cancer, gastric cancer and colorectal cancer. It is a prodrug of fluoropyrimidine carbamate that needs to be converted in vivo into 5-fluorouracil (5-FU), the active form or metabolite.
| Targets |
DNA/RNA Synthesis
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
|
|
| Cell Assay |
In 96-well plates, HepG2 and LS174T WT or LS174T-c2 cells are seeded in the upper and lower chambers of 8-well strip membranes, respectively. The cells that are expanding exponentially are subjected to escalating levels of capecitabine. When BR17 MoAB is utilized in the experiments, 100 ng/mL of the moab is added to the medium in addition to 750 ng/mL of ZB4 MoAB. The traditional colorimetric MTT test is used to evaluate the viability of LS174T following a continuous exposure of 72 hours.
|
|
| Animal Protocol |
|
|
| References |
| Molecular Formula |
C15H22FN3O6
|
|
|---|---|---|
| Molecular Weight |
359.35
|
|
| Exact Mass |
359.15
|
|
| Elemental Analysis |
C, 50.14; H, 6.17; F, 5.29; N, 11.69; O, 26.71
|
|
| CAS # |
154361-50-9
|
|
| Related CAS # |
|
|
| Appearance |
Solid powder
|
|
| SMILES |
CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@H]2[C@@H]([C@@H]([C@H](O2)C)O)O
|
|
| InChi Key |
GAGWJHPBXLXJQN-UORFTKCHSA-N
|
|
| InChi Code |
InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1
|
|
| Chemical Name |
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
|
|
| Synonyms |
Capecitabine; RO09-1978; Ro-091978000; Ro 091978000; Ro091978000; RO-09-1978; RO 09-1978; Abbreviation: CAPE. Trade name: Xeloda
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.79 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.79 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.79 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 25 mg/mL (69.57 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. Solubility in Formulation 5: 20 mg/mL (55.66 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7828 mL | 13.9140 mL | 27.8280 mL | |
| 5 mM | 0.5566 mL | 2.7828 mL | 5.5656 mL | |
| 10 mM | 0.2783 mL | 1.3914 mL | 2.7828 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02491697 | Active Recruiting |
Biological: DC-CIK Immunotherapy Drug: Capecitabine Monotherapy |
Breast Cancer | The First People's Hospital of Changzhou |
February 2016 | Phase 2 |
| NCT02861300 | Active Recruiting |
Drug: Capecitabine Drug: CB-839 |
Colorectal Cancer Solid Tumor |
David Bajor | September 12, 2016 | Phase 1 Phase 2 |
| NCT04034251 | Active Recruiting |
Drug: Paclitaxel Drug: Capecitabine |
Gastric Adenocarcinoma Gastric Cancer |
National Cancer Institute (NCI) |
June 9, 2020 | Phase 2 |
| NCT02669173 | Active Recruiting |
Drug: Capecitabine Drug: Bevacizumab |
Glioblastoma | Case Comprehensive Cancer Center |
October 11, 2016 | Phase 1 |
| NCT03377387 | Active Recruiting |
Drug: Capecitabine Drug: Neratinib |
Breast Cancer | Memorial Sloan Kettering Cancer Center |
December 13, 2017 | Phase 1 Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA